Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.83 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931650 | 0.91 | BRAF (1.00) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3934902 | 0.90 | BRAF (1.00) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3934816 | 0.89 | BRAF (0.83) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3939123 | 0.89 | BRAF (0.83) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3936471 | 0.88 | BRAF (1.00) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3933651 | 0.88 | BRAF (0.81) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3933392 | 0.88 | LCK (0.79) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL4012382 | 0.87 | BRAF (0.80) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3939889 | 0.87 | BRAF (1.00) | BRAFCYP2C9LCKABL1KIT | |
| SCHEMBL3939806 | 0.87 | BRAF (0.79) | BRAFCYP2C9LCKMAPK14BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |